Equillium pushes for breakthrough status despite missing primary endpoint
Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s
Duchenne muscular dystrophy: Five trials to watch
IGC Pharma posts promising interim data for Alzheimer’s therapy
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trial
Analysis
View More
Themes
View MoreMastering compliance and copyright in healthcare and MedComms
In the fast-paced world of medical communications, understanding reuse rights and copyright compliance is critical, particularly in today’s ever-evolving technological landscape.
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
1 of 2
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
MWC Barcelona 2025: Maximizing 5G network value in the age of AI
Driving bioscience innovation: How Teesside University empowers industry breakthroughs
The AI advantage in discovering new medicines
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline